ProAssurance’s underwhelming sale price: Lessons for other insurers
  • X
  • LinkedIn
  • Show more sharing options
  • Print
  • X
  • LinkedIn
  • Free Trial
  • Log in

ProAssurance’s underwhelming sale price: Lessons for other insurers

What insurers can learn from the history that led to this deal.

By Amit Kumar Henry Meiners Noah Marchese
March 24, 2025
  • X
  • LinkedIn
  • Show more sharing options
  • Print
  • X
  • LinkedIn
ProAssurance-share-price-lead-v2.png

Last week, The Doctors Company announced the acquisition of ProAssurance, the last remaining publicly traded medical malpractice (medmal) specialist, for $25 per share or $1.3

Request a free trial:

Fuel a smarter strategy with our actionable market intelligence

    • Gain a competitive edge and accelerate decision-making
    • Be empowered by insights that transform confusion to clarity
    • Uncover growth opportunities and prepare for potential threats
Request a free trial Already a subscriber? Log in now

Topics

Research M&A Insurers Medmal (Medical malpractice) Claims trends Legal
Gift this article